Participant flow

Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer · Source last updated 2019-01-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive gemcitabine IV over 30 minutes followed by docetaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Gemcitabine Hydrochloride: Given IV Docetaxel: Given IV

   id

   FG000

   title

   Treatment (Gemcitabine Hydrochloride, Docetaxel)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Wrong Cell Type

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Wrong Primary

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Never Treated

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         28

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         24

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         4

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

This trial was opened to patient entry on March 7, 2005 and was closed to accrual on October 29, 2007

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice